Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
This article has no abstract
Epistemonikos ID: fae5a0127b337b613f37195a0d45d83e451f23a7
First added on: Apr 17, 2025